
    
      The primary purpose is to assess the pharmacokinetics of Saxagliptin, 5-hydroxy Saxagliptin,
      and Metformin in pediatric subjects aged 10 to 17 years with T2DM following oral
      administration of Saxagliptin and Metformin XR fixed dose combination tablet and
      co-administration of Saxagliptin and GlucophageÂ® (Metformin) IR tablets
    
  